The significant differential gene expression with poor prognosis of patient’s survival, genetic alterations, and immune cell infiltration underscores the CDKN2A potential as a valuable biomarker and its expression may help clinicians, biotechnologists, and oncologists to navigate more therapeutic strategies and predict patient outcomes more accurately during COAD progression. Here, CDKN2A is linked to colon adenocarcinoma.